{"id":"NCT00760435","sponsor":"University of California, San Diego","briefTitle":"Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease","officialTitle":"Infliximab (RemicadeÂ®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2008-09-26","resultsPosted":"2014-11-13","lastUpdate":"2014-11-24"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Kawasaki Disease"],"interventions":[{"type":"DRUG","name":"Infliximab","otherNames":["Remicade"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).","primaryOutcome":{"measure":"The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion","timeFrame":"10 weeks","effectByArm":[{"arm":"Infliximab","deltaMin":11,"sd":null},{"arm":"Placebo","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Weeks","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["18672254","18571548","17301297","15574639","15870671","24572997","23901839","23305955"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":98},"commonTop":["URI","Vomiting/nausea/abdominal pain","Worsening of WBC","Coronary artery abnormality","Rash"]}}